Alumis files for IPO ahead of Phase 3 studies for second-generation TYK2 inhibitor

Precision immunology startup Alumis has filed to go public, pitching itself to Wall Street just three months after raising $259 million from private investors.

Alumis didn’t include an estimated figure in its initial filing but noted that proceeds will support its lead drug through multiple Phase 2 and Phase 3…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks